LA MINOCICLINA, ENFERMEDAD DE LYME, Y EL COVID 19.
THE MINOCYCLINE, THE LYME DISEASE, AND COVID 19.
ACTUALIZADO 2025 -2026
NOTA: Esta es la cuarta (4ta) publicación que hago sobre la MINOCICLINA, la primera de ellas fue publicada bajo el nombre: LA MINOCICLINA, LO BUENO LO MALO Y LO FEO, la cual termino siendo publicada por la REVISTA DERMATOLOGICA DE CHILE. Posteriormente hice una actualización bajo el nombre de LA MINOCICLINA, EN LA ENFERMEDAD DE LYME que fue publicada en la REVISTA ONLINE INVESTIGATIVE JOURNAL OF DERMATOLOGY, luego lance una nueva version que denomine LA MINOCICLINA NUEVOS USOS PARA UN VIEJO ANTIBIÓTICO, y hoy te traigo, otra nueva REVISION donde hablaremos LA MINOCICLINA EN LA ENFERMEDAD DE LYME, Y EN EL COVID 19.
EDITORIAL ESPAÑOL
===================
Hola amigos de la red DERMAGIC EXPRESS te trae hoy un tema bastante
interesante LA
MINOCICLINA EN LA ENFERMEDAD DE LYME, Y EN EL COVID 19.
Primeramente te voy a decir una vez más, que no es la primera vez que
hablo de este "VIEJO ANTIBIÓTICO", familia de las tetraciclinas el cual
hace muchos años, repito hace muchos años se le descubrió la HABILIDAD o
CAPACIDAD de acabar o destruir unos cuantos MICROORGANISMOS o
bacterias las cuales los científicos consideraban prácticamente
"INVENCIBLES" o "IMPOSIBLES" de exterminar.
El primero y quizá mas importante que te voy a mostrar es EL BACILO DE HANSEN, el MYCOBACTERIUM LEPRAE, bacteria milenaria y apocalíptica, causante de la LEPRA, descrita en la BIBLIA en el capitulo LEVÍTICO, descrito y descubierto por el científico Alemán ARMAUER HANSEN en él año de 1.873.
Esta MYCOBACTERIA se le considero "INVENCIBLE" hasta que aparecieron las SULFONAS, (DDS) diaminodifenilsulfona, LA RIFAMPICINA, Y el CLOFAZIMINE. Te estoy hablando de los años 1.940-1.945 cuando aparecieron estas medicinas, que conjuntamente con la INMUNOTERAPIA, decretaron el cierre de las LEPROSERÍAS en todo el mundo. Todo esto te lo conté en LOS CAPITULOS SOBRE LA LEPRA.
El primero y quizá mas importante que te voy a mostrar es EL BACILO DE HANSEN, el MYCOBACTERIUM LEPRAE, bacteria milenaria y apocalíptica, causante de la LEPRA, descrita en la BIBLIA en el capitulo LEVÍTICO, descrito y descubierto por el científico Alemán ARMAUER HANSEN en él año de 1.873.
Esta MYCOBACTERIA se le considero "INVENCIBLE" hasta que aparecieron las SULFONAS, (DDS) diaminodifenilsulfona, LA RIFAMPICINA, Y el CLOFAZIMINE. Te estoy hablando de los años 1.940-1.945 cuando aparecieron estas medicinas, que conjuntamente con la INMUNOTERAPIA, decretaron el cierre de las LEPROSERÍAS en todo el mundo. Todo esto te lo conté en LOS CAPITULOS SOBRE LA LEPRA.
Y algunos años después llego LA MINOCICLINA (MINO), un antibiótico que está cambiando la historia de la evolución de algunas enfermedades hoy día. Este antibiótico es familia de las "viejas" TETRACICLINAS, cuyo primer antibiótico fue sintetizado en él año de 1.940 bajo el nombre de CLORTETRACICLINA (AUREOMICINA) por el científico Benjamín Minge Duggar, del LABORATORIO LEDERLE.
Posterior a este descubrimiento fueron apareciendo en el mercado otras TETRACICLINAS: OXITETRACICLINA, DEMECLOCICLINA, LYMECICLINA, MECLOCICLINA. METHACICLINA, ROLITETRACICLINA, TIGECICLINA Y nuestra "FAMOSA" MINOCICLINA.
Específicamente la MINOCICLINA (MINO) nació en él año 1.961 y colocada en el mercado en el año de 1.967, bajo el nombre DE MINOCIN, el cual existe todavía hoy día. Han pasado 50 años, medio siglo desde su descubrimiento. Su uso principal fue destinado a combatir la bacteria del ACNE, pero posteriormente se le describieron otras propiedades.
En el año de 1.999 17, de Marzo, yo lance a la red el articulo LA MINOCICLINA, LO BUENO, LO MALO Y LO FEO, el cual fue publicado en la REVISTA DE DERMATOLOGÍA DE EL PAÍS CHILE, y lo relance actualizado el 10 de febrero de 2.017 bajo el nombre de MINOCICLINA ALZHEIMER Y OTROS TRASTORNOS NEUROLOGICOS, por sus nuevos usos. Es decir tengo casi 20 años hablándoles de las bondades de este antibiótico que lo diferencian del resto de sus congéneres.
En los años 80 y 90 se demostró que la MINOCICLINA tiene un efecto altamente potente contra EL MYCOBACTERIUM LEPRAE y se diseñaron varios esquemas terapéuticos en conjunto con otros antibióticos como la OFLOXACINA, CLARITROMICINA Y AMOXICILINA, para combatir la LEPRA, referencias 3,4,5,6,7,8.
Últimamente se le descubrió su efecto NEURO PROTECTOR, siendo utilizado hoy día en enfermedades como el ALZHEIMER, PARKINSON, ESQUIZOFRENIA, TRASTORNOS BIPOLARES ENCEFALOMIELITIS AUTO-INMUNE Y ESCLEROSIS MULTIPLE.
Entonces te estarás preguntando que "TIENE" este antibiótico que lo diferencia de sus congéneres, y te lo voy a decir: CLARO y CIENTÍFICAMENTE
1.) TIENE UN MAYOR AMPLIO ESPECTRO QUE OTRAS TETRACICLINAS.
2.) TIENE UN TIEMPO DE VIDA MEDIA EN EL SUERO: 2 A 4 VECES MAYOR QUE OTRAS TETRACICLINAS.
3.) TIENE MAYOR LIPOSOLUBILIDAD QUE LAS DEMAS TETRACICLINAS LO CUAL LE PERMITE TENER UNA MAYOR PENETRACIÓN EN LOS TEJIDOS COMO PRÓSTATA, CEREBRO Y SISTEMA NERVIOSO CENTRAL.
Me estas entendiendo? me estas copiando? Me estas sintiendo ?
Es por ello que hoy día se le ha encontrado a este antibiótico con MEDIO SIGLO EN EL MERCADO usos que el humano jamás pensó que podría ser útil.
AHORA VOY A EXPLICARTE LA RELACIÓN DE LA ENFERMEDAD DE LYME CON LA MINOCICLINA, lo cual ya explique en las versiones anteriores, pero vale la pena recordar.
Si te pones a revisar las más conocidas BASES DE DATOS te encontraras que los antibióticos más utilizados en la ENFERMEDAD DE LYME del grupo de las tetraciclinas son la OXITETRACICLINA, y ULTIMAMENTE la TIGECICLINA, sin descartar por supuesto la MINOCICLINA.
Y el más utilizado, de la familia de las PENICILINAS, LA DOXICICLINA, También un antibiótico antiguo que nació en 1.961 y salió al mercado en 1.967 por el laboratorio PFIZER
Hace unos días leí un artículo de un paciente con ENFERMEDAD DE LYME que desarrollo parálisis de BELL y su tratamiento con DOXICICLINA fracaso, le recetaron MINOCICLINA y el paciente se sano. En muchos artículos aparece como primera opción contra la ENFERMEDAD DE LYME la DOXICILINA, y otros, pero no la MINOCILINA y mucho menos la PENICLINA G, de la cual no encontré casi estudios.
Pero si te pones a "ESCARBAR" bien las bases de datos te encuentras con la "SORPRESA" de que la MINOCICLINA en los años 80s y 90s, se le descubrió su efectividad en la ENFERMEDAD DE LYME, de hecho también hay algunos (pocos) estudios donde se demuestra que la PENICILINA G PROCAINICA también es efectiva en esta enfermedad, y aquí viene la gran pregunta ?
Porque estos dos antibióticos PENICILINA G Y MINOCICLINA (MINO) no son utilizados como PRIMERA ELECCIÓN CONTRA enfermedad de LYME? O en combinación con otros? Yo se que algunos científicos SI UTILIZAN LA MINOCICLINA, pero muy pocos o casi ninguno la PENICILINA sabiendo que la BORRELIA BURGDORFERI (EL AGENTE CAUSAL) ES UNA ESPIROQUETA como el TREPONEMA PALLIDUM que causa la SÍFILIS y que "MUERE" con PENICILINA.
Esta revisión la estoy haciendo para RECORDARLES A ALGUNOS CIENTÍFICOS que la MINOCICLINA, fue uno de los primeros antibióticos que luego de LA DAPSONA, RIFAMPICINA Y CLOFAZIMINA, tiene la habilidad, capacidad de ELIMINAR UN MICRO-ORGANISMO tan "DURO DE MATAR" como el MYCOBACTERIUM LEPRAE, esto habla por sí solo de su "POTENCIA" no importa lo "VIEJO" que sea.
Que quiero decirte con esto ? que tengo conocimiento del TREMENDO problema de salud a nivel mundial que está ocasionando la BORRELIA BURGORFERI y tienes a tu disposición 2 ANTIBIÓTICOS como PENICILINA G Y MINOCICLINA que pueden ayudarte con todos esos pacientes, sobre todo los que padecen de NEUROBORRELIOSIS, por la gran capacidad que tiene este antibiótico (MINOCICLINA) de penetrar los tejidos cerebrales.
También tienes OFLOXACINA Y CLARITROMICINA, entonces les sugiero a los investigadores UTILIZARLOS en la ENFERMEDAD DE LYME.
Por supuesto contra esta ENFERMEDAD DE LYME se ha utilizado numerosos antibióticos como: ciprofloxacino, amoxicilina, eritromicina, tetraciclina, cefalosporinas y otros
Para finalizar, como te dije en una de mis revisiones sobre la ENFERMEDAD DE LYME...
"NO DEJES DE RECLAMAR TUS DERECHOS SOBRE SALUD, TRATAMIENTOS Y PÓLIZAS DE SEGURO, PERO TAMBIÉN NO DEJES DE HACER UN BUEN TRATAMIENTO... NO SE RINDAN..."
Y también se cumple el viejo axioma:
"...LOS ARTÍCULOS CIENTÍFICOS NO PRESCRIBEN POR MAS "VIEJA" QUE SEA LA DATA DE PUBLICACIÓN..."
Y también podemos resumir que dos viejos antibióticos como la DOXICICLINA, familia de las penicilinas y la MINOCICLINA, familia de las tetraciclinas inventadas hace 50 años, son quienes están dando la gran batalla contra LA ENFERMEDAD DE LYME hoy dia. Yo particularmente creo que la MINOCICLINA es mas potente.
1.) LA MINOCICLINA Y COVID 19:
En el año 2020 llego la Pandemia del Sars-Cov-2, o COVID 19,
el segundo CORONAVIRUS, pues el primero apareció en el año 2003,
pero no tuvo tanta relevancia como este.
La aparición de este VIRUS, tomo al mundo por sorpresa,
desconociéndose los tratamientos mas adecuados, obligando esto a un
encierro mundial de la población en sus hogares.
Poco a poco fuero apareciendo las alternativas terapéuticas porque
NO EXISTÍA VACUNA para tal virus, y las que posteriormente fueron
INVENTADAS tipo ARN Mensajero, han dejado una ola de SECUELAS,
motivo por el cual estas VACUNAS
están altamente cuestionadas hoy dia.
Existe un DEBATE MUNDIAL sobre si deben suspenderse o no estas
vacunas tipo ARN mensajero.
Entre las alternativas TERAPÉUTICAS que aparecieron están el
HIDOXICLOROQUINA, Y LA IVERMECTINA, ambas medicinas antiparasitarias, que provocaron una POLÉMICA que
todavía hoy esta en la palestra. TAMBIÉN apareció el antiviral
REMDESIVIR, y antibióticos como la
LEVOFLOXACINA, AZITROMICINA, DOXICICLINA, y también la
MINOCICLINA.
Los científicos ITALIANOS fueron los primeros en descubrir que los
VENTILADORES MECÁNICOS NO FUNCIONABAN, pues se trataba de una
COAGULACIÓN INTRA VASCULAR DISEMINADA,
provocada por el VIRUS. Allí comenzaron a utilizarse los
ANTICOAGULANTES Y el ZINC como preventivos, aparte de altas dosis de
ESTEROIDES TIPO DEXAMETASONA.
2.) MINOCICLINA EN COVID 19 AGUDO:
LA MINOCICLINA NO DEMOSTRÓ
SER de gran utilidad en el
tratamiento agudo del COVID-19 (SARS-CoV-2), a
diferencia de los antibióticos previamente señalados.
3.) MINOCICLINA EN COVID LARGO/POST COVID 19:
4.) MECANISMOS PROPUESTOS CONTRA EL VIRUS SARS-CoV-2:
1- ANTIVIRAL indirecto: Bloquea entrada viral vía MMP-9, estabiliza lisosomas endosomal.
2.- REDUCE LA DENOMINADA "TORMENTA DE CITOQUINAS", mediante un mecanismo antiinflamatorio: Inhibe NF-κB, microglía y
citoquinas (IL-6, TNF-α).
3.- NEUROPROTECTOR: Este antibiótico tiene la propiedad de cruzar la barrera hemato encefálica; es decir llega al cerebro, por lo tanto es útil en la FATIGA post-COVID; quizá este es uno de sus efectos mas beneficiosos en el llamado"POST COVID-19".
4.- ANTIBACTERIANO: Protege contra sobreinfecciones secundarias.
Estos eventos COINCIDEN con lo descrito sobre este antibiótico que hice en varias oportunidades.
5.) LAS EVIDENCIAS CLÍNICAS (2025):
1.) En el COVID agudo: Estudios fase II/III (2020-2022): Los estudios realizados no mostraron reducción mortalidad/hospitalización, en contraste con otras alternativas, como dexametasona/remdesivir, por lo tanto la CONCLUSION DE LAS guías WHO/NIH, fue NO RECOMENDADO.
2.) En el COVID largo:
A.- Estudio Miwa 2025:
Minociclina oral (100-200mg/día) en 19 pacientes COVID largo →
84% de mejoría de síntomas (fatiga, dolor, niebla mental) a
las 4 semanas.
B.- Otros Estudios pilotos: Reducción 60-70% fatiga crónica, seguridad buena (náuseas 10%).
6.) DOSIS Y ADMINISTRACIÓN PROPUESTA:
- En COVID largo (off-label):
B.- Otros Estudios pilotos: Reducción 60-70% fatiga crónica, seguridad buena (náuseas 10%).
6.) DOSIS Y ADMINISTRACIÓN PROPUESTA:
- En COVID largo (off-label):
La PRESENTACIÓN DE LA MINOCICLINA ES: Capsulas de 100 mgr.
100mg VO 2x/día x 4-8 semanas (200 MGR /DIA)
Monitoreo: Función renal/hepática semanal
Contraindicaciones: Embarazo, lupus, <8 años
7.) ESTADO APROBATORIO:
No aprobado por la FDA, ni la EMA (Comisión Europea) para el COVID; su estado aprobatorio sigue siendo: solo acné, rosácea, artritis reumatoide.
7.) ESTADO APROBATORIO:
No aprobado por la FDA, ni la EMA (Comisión Europea) para el COVID; su estado aprobatorio sigue siendo: solo acné, rosácea, artritis reumatoide.
Uso Off-label: solo en el COVID largo con NEUROINFLAMACION PERSISTENTE.
8.) CONCLUSIONES:
8.) CONCLUSIONES:
Como ha sido explicado en este articulo en los previamente
publicados, un antibiótico creado hace mas de 50 años todavía sigue
siendo útil no solo en el ACNE y ROSÁCEA (principales usos), sino
que se le descubrieron propiedades
ANTIINFLAMATORIAS y NEUROPROTECTORAS, y hoy dia 2026, sigue siendo ÚTIL en las patologías descritas,
incluyendo el MORTAL COVID 19, en su version larga o POST
COVID-19.
Saludos a todos
Dr. José Lapenta.
Dr. José M. Lapenta.
Saludos a todos
Dr. José Lapenta.
NOTE: This is the fourth (4th) publication I have made on MINOCYCLINE, the first of them was published under the name: MINOCYCLINE, THE GOOD THE BAD AND THE UGLY, which ended up being published by the CHILEAN DERMATOLOGICAL JOURNAL. Subsequently, I made an update under the name of MINOCYCLINE IN LYME DISEASE, which was published in the ONLINE INVESTIGATIVE JOURNAL OF DERMATOLOGY, then I launched a new version that I called MINOCYCLINE NEW USES FOR AN OLD ANTIBIOTIC, and today I bring you another new REVIEW where we will talk about MINOCYCLINE LYME DISEASE, AND COVID 19.
EDITORIAL ENGLISH
===================
Hello friends of the DERMAGIC EXPRESS network, today it brings you a quite interesting topic MINOCYCLINE, LYME DISEASE, AND COVID 19. First of all I
will tell you once again that this is not the first time I speak of this
"OLD ANTIBIOTIC" family of tetracyclines which many years ago, I
repeat many years ago was discovered the ABILITY or CAPACITY
to finish or destroy many MICROORGANISMS or bacteria which scientists considered
practically "INVINCIBLE" or "IMPOSSIBLE" to exterminate.
The first and perhaps most important that I will show you is THE HANSEN'S BACILLI, the MYCOBACTERIUM LEPRAE, a millenary and apocalyptic bacterium, responsible for LEPROSY mentioned in the BIBLE in the LEVITIC'S chapter , described and discovered by the scientist ARMAUER HANSEN in The year of 1.873.
This MYCOBACTERIUM was considered "INVINCIBLE" until SULPHONES appeared, (DDS) diaminodiphenylsulfone, RAFAMPICINE, and CLOFAZIMINE. I am speaking of the years 1940-1945 when these medicines appeared, which together with IMMUNOTHERAPY, decreed the closure of LEPROSERIES throughout the world wide. All this I told you in THE LEPROSY CHAPTERS.
And a few years later came the MINOCYCLINE (MINO), an antibiotic that is changing the history of the evolution of some diseases today. This antibiotic is a family of "old" TETRACYCLINES whose first antibiotic was synthesized in the year 1.940 under the name CHLORTETRACYCLINE (AUREOMYCIN) by the scientist Benjamin Minge Duggar, of LABORATORY LEDERLE.
Subsequent to this discovery, other TETRACYCLINES appeared on the market: OXYTETRACYCLINE, DEMECLOCYCLINE, LYMECYCLINE, MECLOCYCLINE. METHACYCLINE, ROLITETRACYCLINE TIGECYCLINE AND OUR "FAMOUS" MINOCYCLINE.
Specifically MINOCYCLINE (MINO) was born in 1.961 and placed on the market in the year 1.967, under the name MINOCIN, which still exists today. It's been 50 years, half a century since its discovery. Its main use was to combat ACNE bacteria, but other properties were later described.
In March 1.999, 17, I launched the article THE MINOCYCLINE, THE GOOD, THE BAD AND THE UGLY, which was published in the Dermatology's magazine of Chile, and updated on February 10, 2,017 under the name MINOCYCLINE ALZHEIMER AND OTHER NEUROLOGICAL DISORDERS, for its new uses. This means that I have 20 years talking about the benefits of this antibiotic that differentiate it from the rest of its congeneries.
In the 1980s and 1990s, MINOCYCLINE was shown to have a highly potent effect against MYCOBACTERIUM LEPRAE and several therapeutic regimens were designed in conjunction with other antibiotics such as OFLOXACINE, CLARITROMYCIN, AND AMOXYCYLIN to combat LEPROSY, references 3,4,5,6,7,8.
Recently it has been discovered its effect NEUROPROTECTOR, being used today in diseases like ALZHEIMER, PARKINSON, SCHIZOPHRENIA, BIPOLAR DISORDERS, AUTOIMMUNE ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS.
Then you'll be asking yourself "WHAT HAS" this antibiotic that THAT MAKES IT DIFFERENT FROM ITS CONGENERIES, and I'll tell you: CLEAR and SCIENTIFICALLY
1.) HAS MORE BROAD SPECTRUM THAN OTHER TETRACYCLINES.
2.) HAVE AN AVERAGE LIFETIME IN SERUM: 2 TO 4 TIMES GREATER THAN OTHER TETRACYCLINES.
3.) IT HAS GREATER LIPOSOLUBILITY THAN OTHER TETRACYCLINES WHICH ALLOWS IT TO HAVE GREATER PENETRATION IN THE TISSUES AS PROSTATE, BRAIN AND CENTRAL NERVOUS SYSTEM.
Are you understanding me? you are copying me? Are you feeling me ?
That is why today we have found this antibiotic with uses that the human never thought could be useful.
NOW I AM GOING TO EXPLAIN THE RELATIONSHIP OF LYME DISEASE WITH MINOCYCLINE.
If you go to review the most known DATABASES you will find that the antibiotics most used in LYME DISEASE of the group of tetracyclines are OXYTETRACYCLINE, and LATELY TIGECYCLINE, without ruling out the MINOCYCLINE.
And the most used, family of PENICILLINS, DOXYCYCLINE, Also an old antibiotic that was born in 1.961 and came on the market in 1.967 by the laboratory PFIZER
A few days ago I read an article of a patient with LYME DISEASE who developed BELL'S Paralysis and its treatment with DOXYCYCLINE failure, they prescribed MINOCYCLINE and the patient was healthy. In many articles it appears as a first option against LYME DISEASE DOXYCYLINE, and others, but not the MINOCYCLINE, much less the G PENICILLIN, of which I did not find almost studies.
But if you get to "DIG" well the databases you find the "SURPRISE" that MINOCYCLINE in the 80s and 90s, was discovered its effectiveness in LYME DISEASE, in fact there are also some (few) Studies where it is shown that PENICILLIN G PROCAINIC is also effective in this disease, and here comes the big question
Why ? these two antibiotics G PENICILLIN AND MINOCYCLINE (MINO) are not used as the FIRST ELECTION against LYME disease? Or in combination with others? I know that some scientists DO USE THE MINOCYCLINE, but very few or almost none of the G PENICILLIN, knowing that the BORRELIA is a SPIROQUETTE like the TREPONEMA PALLIDUM that causes SYPHIILIS and that it "DIES" with PENICILLIN.
This review I am doing to REMEMBER TO SOME SCIENTISTS that MINOCYCLINE was one of the first antibiotics that after THE DAPSONE, RIFAMPICIN and CLOFAZYMINE, has the ability, to eliminate a MICRO-ORGANISM as "HARD DIE" as the MYCOBACTERIUM LEPRAE, this speaks for itself of its "POWER" no matter how "OLD" it is.
What do I want to tell you with this? That I have knowledge of the "TREMENDOUS" health problem worldwide that is causing the BORRELIA BURGORFERI and you have at your disposal 2 ANTIBIOTICS such as G PENICILLIN and MINOCYCLINE that can help you with all those patients, especially those suffering from NEUROBORRELIOSIS, because of the great capacity it has this antibiotic (MINOCYCLINE) to penetrate the brain tissues.
You also have OFLOXACIN AND CLARITHROMYCIN, so I suggest researchers use them in LYME DISEASE.
Of course against this LYME DISEASE has been used numerous antibiotics such as: ciprofloxacin, amoxicillin, erythromycin, tetracycline, cephalosporins and others.
Finally, as I said in one of my reviews on LYME DISEASE ...
"...DO NOT STOP CLAIMING YOUR RIGHTS ON HEALTH, TREATMENT AND INSURANCE POLICY, BUT ALSO DO NOT HESITATE TO MAKE A GOOD TREATMENT ... DO NOT GIVE UP ..."
And also the old axiom is fulfilled:
"...THE SCIENTIFIC ARTICLES DO NOT PRESCRIBE FOR MORE" OLD "THAT IS THE DATE OF PUBLICATION ..."
And we can also summarize that two old antibiotics like DOXYCYCLINE, a family of penilins and MINOCYCLINE, a family of tetracyclines invented 50 years ago, are the ones who are giving the big battle against LYME DISEASE today. I particularly think MINOCYCLINE is more powerful.
The first and perhaps most important that I will show you is THE HANSEN'S BACILLI, the MYCOBACTERIUM LEPRAE, a millenary and apocalyptic bacterium, responsible for LEPROSY mentioned in the BIBLE in the LEVITIC'S chapter , described and discovered by the scientist ARMAUER HANSEN in The year of 1.873.
This MYCOBACTERIUM was considered "INVINCIBLE" until SULPHONES appeared, (DDS) diaminodiphenylsulfone, RAFAMPICINE, and CLOFAZIMINE. I am speaking of the years 1940-1945 when these medicines appeared, which together with IMMUNOTHERAPY, decreed the closure of LEPROSERIES throughout the world wide. All this I told you in THE LEPROSY CHAPTERS.
And a few years later came the MINOCYCLINE (MINO), an antibiotic that is changing the history of the evolution of some diseases today. This antibiotic is a family of "old" TETRACYCLINES whose first antibiotic was synthesized in the year 1.940 under the name CHLORTETRACYCLINE (AUREOMYCIN) by the scientist Benjamin Minge Duggar, of LABORATORY LEDERLE.
Subsequent to this discovery, other TETRACYCLINES appeared on the market: OXYTETRACYCLINE, DEMECLOCYCLINE, LYMECYCLINE, MECLOCYCLINE. METHACYCLINE, ROLITETRACYCLINE TIGECYCLINE AND OUR "FAMOUS" MINOCYCLINE.
Specifically MINOCYCLINE (MINO) was born in 1.961 and placed on the market in the year 1.967, under the name MINOCIN, which still exists today. It's been 50 years, half a century since its discovery. Its main use was to combat ACNE bacteria, but other properties were later described.
In March 1.999, 17, I launched the article THE MINOCYCLINE, THE GOOD, THE BAD AND THE UGLY, which was published in the Dermatology's magazine of Chile, and updated on February 10, 2,017 under the name MINOCYCLINE ALZHEIMER AND OTHER NEUROLOGICAL DISORDERS, for its new uses. This means that I have 20 years talking about the benefits of this antibiotic that differentiate it from the rest of its congeneries.
In the 1980s and 1990s, MINOCYCLINE was shown to have a highly potent effect against MYCOBACTERIUM LEPRAE and several therapeutic regimens were designed in conjunction with other antibiotics such as OFLOXACINE, CLARITROMYCIN, AND AMOXYCYLIN to combat LEPROSY, references 3,4,5,6,7,8.
Recently it has been discovered its effect NEUROPROTECTOR, being used today in diseases like ALZHEIMER, PARKINSON, SCHIZOPHRENIA, BIPOLAR DISORDERS, AUTOIMMUNE ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS.
Then you'll be asking yourself "WHAT HAS" this antibiotic that THAT MAKES IT DIFFERENT FROM ITS CONGENERIES, and I'll tell you: CLEAR and SCIENTIFICALLY
1.) HAS MORE BROAD SPECTRUM THAN OTHER TETRACYCLINES.
2.) HAVE AN AVERAGE LIFETIME IN SERUM: 2 TO 4 TIMES GREATER THAN OTHER TETRACYCLINES.
3.) IT HAS GREATER LIPOSOLUBILITY THAN OTHER TETRACYCLINES WHICH ALLOWS IT TO HAVE GREATER PENETRATION IN THE TISSUES AS PROSTATE, BRAIN AND CENTRAL NERVOUS SYSTEM.
Are you understanding me? you are copying me? Are you feeling me ?
That is why today we have found this antibiotic with uses that the human never thought could be useful.
NOW I AM GOING TO EXPLAIN THE RELATIONSHIP OF LYME DISEASE WITH MINOCYCLINE.
If you go to review the most known DATABASES you will find that the antibiotics most used in LYME DISEASE of the group of tetracyclines are OXYTETRACYCLINE, and LATELY TIGECYCLINE, without ruling out the MINOCYCLINE.
And the most used, family of PENICILLINS, DOXYCYCLINE, Also an old antibiotic that was born in 1.961 and came on the market in 1.967 by the laboratory PFIZER
A few days ago I read an article of a patient with LYME DISEASE who developed BELL'S Paralysis and its treatment with DOXYCYCLINE failure, they prescribed MINOCYCLINE and the patient was healthy. In many articles it appears as a first option against LYME DISEASE DOXYCYLINE, and others, but not the MINOCYCLINE, much less the G PENICILLIN, of which I did not find almost studies.
But if you get to "DIG" well the databases you find the "SURPRISE" that MINOCYCLINE in the 80s and 90s, was discovered its effectiveness in LYME DISEASE, in fact there are also some (few) Studies where it is shown that PENICILLIN G PROCAINIC is also effective in this disease, and here comes the big question
Why ? these two antibiotics G PENICILLIN AND MINOCYCLINE (MINO) are not used as the FIRST ELECTION against LYME disease? Or in combination with others? I know that some scientists DO USE THE MINOCYCLINE, but very few or almost none of the G PENICILLIN, knowing that the BORRELIA is a SPIROQUETTE like the TREPONEMA PALLIDUM that causes SYPHIILIS and that it "DIES" with PENICILLIN.
This review I am doing to REMEMBER TO SOME SCIENTISTS that MINOCYCLINE was one of the first antibiotics that after THE DAPSONE, RIFAMPICIN and CLOFAZYMINE, has the ability, to eliminate a MICRO-ORGANISM as "HARD DIE" as the MYCOBACTERIUM LEPRAE, this speaks for itself of its "POWER" no matter how "OLD" it is.
What do I want to tell you with this? That I have knowledge of the "TREMENDOUS" health problem worldwide that is causing the BORRELIA BURGORFERI and you have at your disposal 2 ANTIBIOTICS such as G PENICILLIN and MINOCYCLINE that can help you with all those patients, especially those suffering from NEUROBORRELIOSIS, because of the great capacity it has this antibiotic (MINOCYCLINE) to penetrate the brain tissues.
You also have OFLOXACIN AND CLARITHROMYCIN, so I suggest researchers use them in LYME DISEASE.
Of course against this LYME DISEASE has been used numerous antibiotics such as: ciprofloxacin, amoxicillin, erythromycin, tetracycline, cephalosporins and others.
Finally, as I said in one of my reviews on LYME DISEASE ...
"...DO NOT STOP CLAIMING YOUR RIGHTS ON HEALTH, TREATMENT AND INSURANCE POLICY, BUT ALSO DO NOT HESITATE TO MAKE A GOOD TREATMENT ... DO NOT GIVE UP ..."
And also the old axiom is fulfilled:
"...THE SCIENTIFIC ARTICLES DO NOT PRESCRIBE FOR MORE" OLD "THAT IS THE DATE OF PUBLICATION ..."
And we can also summarize that two old antibiotics like DOXYCYCLINE, a family of penilins and MINOCYCLINE, a family of tetracyclines invented 50 years ago, are the ones who are giving the big battle against LYME DISEASE today. I particularly think MINOCYCLINE is more powerful.
1.) MINOCYCLINE AND COVID 19:
In the year 2020, the SARS-CoV-2 Pandemic arrived, or COVID 19, the second CORONAVIRUS, since the first appeared in the year 2003, but it did not have as much relevance as this one.
The appearance of this VIRUS took the world by surprise, with the most appropriate treatments unknown, forcing this to a worldwide lockdown of the population in their homes.
Little by little, therapeutic alternatives began to appear because there was NO VACCINE for such a virus, and those that were subsequently INVENTED, such as messenger RNA type, have left a wave of SEQUELAE, which is why these VACCINES are highly questioned today.
There is a WORLDWIDE DEBATE on whether these messenger RNA type vaccines should be suspended or not.
Among the therapeutic ALTERNATIVES that appeared are HYDROXYCHLOROQUINE and IVERMECTIN, both antiparasitic medicines, which caused a CONTROVERSY that is still in the spotlight today. THE ANTIVIRAL REMDESIVIR also appeared, and antibiotics such as LEVOFLOXACIN, AZITHROMYCIN, DOXYCYCLINE, and also MINOCYCLINE.
The ITALIAN SCIENTISTS were the first to discover that MECHANICAL VENTILATORS DID NOT WORK, because it was a DISSEMINATED INTRAVASCULAR COAGULATION caused by the VIRUS. There, ANTICOAGULANTS and ZINC began to be used as preventives, apart from high doses of STEROIDS like DEXAMETHASONE.
2.) MINOCYCLINE IN ACUTE COVID 19:
MINOCYCLINE DID NOT PROVE to be of great utility in the acute treatment of COVID-19 (SARS-CoV-2), unlike the previously mentioned antibiotics.
3.) MINOCYCLINE IN LONG COVID/POST COVID 19:
In the cases called long COVID-19 (SARS-CoV-2), or POST COVID-19, MINOCYCLINE has proven to be USEFUL, because as described earlier, this "old" antibiotic has been described with NEUROPROTECTIVE, ANTIVIRAL (indirect) and ANTIINFLAMMATORY effects.
4.) PROPOSED MECHANISMS AGAINST THE SARS-CoV-2 VIRUS:
1- ANTIVIRAL indirect: Blocks viral entry via MMP-9, stabilizes endosomal lysosomes.
2.- REDUCES the so-called "CYTOKINE STORM", through an anti-inflammatory mechanism: Inhibits NF-κB, microglia and cytokines (IL-6, TNF-α).
3.- NEUROPROTECTIVE: This antibiotic has the property of crossing the blood-brain barrier; that is, it reaches the brain, therefore it is useful in post-COVID FATIGUE; perhaps this is one of its most beneficial effects in the so-called "POST COVID-19".
4.- ANTIBACTERIAL: Protects against secondary superinfections.
These events COINCIDE with what was described about this antibiotic that I have done on several occasions.
5.) CLINICAL EVIDENCE (2025):
1.) In acute COVID: Phase II/III studies (2020-2022): The studies conducted did not show reduction in mortality/hospitalization, in contrast to other alternatives like dexamethasone/remdesivir, therefore the CONCLUSION OF THE WHO/NIH guidelines was NOT RECOMMENDED.
2.) In long COVID:
A.- Study Miwa 2025: Oral minocycline (100-200mg/day) in 19 long COVID patients → 84% improvement in symptoms (fatigue, pain, brain fog) at 4 weeks.
B.- Other pilot studies: Reduction 60-70% chronic fatigue, good safety (nausea 10%).
6.) PROPOSED DOSE AND ADMINISTRATION:
- In long COVID (off-label):
THE PRESENTATION OF MINOCYCLINE IS: 100 mg capsules.
100mg PO 2x/day x 4-8 weeks (200 MG/DAY)
Monitoring: Renal/hepatic function weekly
Contraindications: Pregnancy, lupus, <8 years
7.) APPROVAL STATUS:
Not approved by the FDA, nor EMA (European Commission) for COVID; its approval status remains: only acne, rosacea, rheumatoid arthritis.
Off-label use: only in long COVID with PERSISTENT NEUROINFLAMMATION.
8.) CONCLUSIONS:
As explained in this article and the previously published ones, an antibiotic created more than 50 years ago is still useful not only in ACNE and ROSACEA (main uses), but ANTI-INFLAMMATORY and NEUROPROTECTIVE properties were discovered, and today 2026, it continues to be USEFUL in the described pathologies, including the DEADLY COVID 19, in its long or POST COVID-19 version.
Greetings to all
Dr. José Lapenta.
Dr. José M. Lapenta.
=======================================================================
REFERENCIAS BIBLIOGRÁFICAS/ BIBLIOGRAPHICAL REFERENCES
=======================================================================
In the year 2020, the SARS-CoV-2 Pandemic arrived, or COVID 19, the second CORONAVIRUS, since the first appeared in the year 2003, but it did not have as much relevance as this one.
The appearance of this VIRUS took the world by surprise, with the most appropriate treatments unknown, forcing this to a worldwide lockdown of the population in their homes.
Little by little, therapeutic alternatives began to appear because there was NO VACCINE for such a virus, and those that were subsequently INVENTED, such as messenger RNA type, have left a wave of SEQUELAE, which is why these VACCINES are highly questioned today.
There is a WORLDWIDE DEBATE on whether these messenger RNA type vaccines should be suspended or not.
Among the therapeutic ALTERNATIVES that appeared are HYDROXYCHLOROQUINE and IVERMECTIN, both antiparasitic medicines, which caused a CONTROVERSY that is still in the spotlight today. THE ANTIVIRAL REMDESIVIR also appeared, and antibiotics such as LEVOFLOXACIN, AZITHROMYCIN, DOXYCYCLINE, and also MINOCYCLINE.
The ITALIAN SCIENTISTS were the first to discover that MECHANICAL VENTILATORS DID NOT WORK, because it was a DISSEMINATED INTRAVASCULAR COAGULATION caused by the VIRUS. There, ANTICOAGULANTS and ZINC began to be used as preventives, apart from high doses of STEROIDS like DEXAMETHASONE.
2.) MINOCYCLINE IN ACUTE COVID 19:
MINOCYCLINE DID NOT PROVE to be of great utility in the acute treatment of COVID-19 (SARS-CoV-2), unlike the previously mentioned antibiotics.
3.) MINOCYCLINE IN LONG COVID/POST COVID 19:
In the cases called long COVID-19 (SARS-CoV-2), or POST COVID-19, MINOCYCLINE has proven to be USEFUL, because as described earlier, this "old" antibiotic has been described with NEUROPROTECTIVE, ANTIVIRAL (indirect) and ANTIINFLAMMATORY effects.
4.) PROPOSED MECHANISMS AGAINST THE SARS-CoV-2 VIRUS:
1- ANTIVIRAL indirect: Blocks viral entry via MMP-9, stabilizes endosomal lysosomes.
2.- REDUCES the so-called "CYTOKINE STORM", through an anti-inflammatory mechanism: Inhibits NF-κB, microglia and cytokines (IL-6, TNF-α).
3.- NEUROPROTECTIVE: This antibiotic has the property of crossing the blood-brain barrier; that is, it reaches the brain, therefore it is useful in post-COVID FATIGUE; perhaps this is one of its most beneficial effects in the so-called "POST COVID-19".
4.- ANTIBACTERIAL: Protects against secondary superinfections.
These events COINCIDE with what was described about this antibiotic that I have done on several occasions.
5.) CLINICAL EVIDENCE (2025):
1.) In acute COVID: Phase II/III studies (2020-2022): The studies conducted did not show reduction in mortality/hospitalization, in contrast to other alternatives like dexamethasone/remdesivir, therefore the CONCLUSION OF THE WHO/NIH guidelines was NOT RECOMMENDED.
2.) In long COVID:
A.- Study Miwa 2025: Oral minocycline (100-200mg/day) in 19 long COVID patients → 84% improvement in symptoms (fatigue, pain, brain fog) at 4 weeks.
B.- Other pilot studies: Reduction 60-70% chronic fatigue, good safety (nausea 10%).
6.) PROPOSED DOSE AND ADMINISTRATION:
- In long COVID (off-label):
THE PRESENTATION OF MINOCYCLINE IS: 100 mg capsules.
100mg PO 2x/day x 4-8 weeks (200 MG/DAY)
Monitoring: Renal/hepatic function weekly
Contraindications: Pregnancy, lupus, <8 years
7.) APPROVAL STATUS:
Not approved by the FDA, nor EMA (European Commission) for COVID; its approval status remains: only acne, rosacea, rheumatoid arthritis.
Off-label use: only in long COVID with PERSISTENT NEUROINFLAMMATION.
8.) CONCLUSIONS:
As explained in this article and the previously published ones, an antibiotic created more than 50 years ago is still useful not only in ACNE and ROSACEA (main uses), but ANTI-INFLAMMATORY and NEUROPROTECTIVE properties were discovered, and today 2026, it continues to be USEFUL in the described pathologies, including the DEADLY COVID 19, in its long or POST COVID-19 version.
Greetings to all
Dr. José Lapenta.
Dr. José M. Lapenta.
=======================================================================
REFERENCIAS BIBLIOGRÁFICAS/ BIBLIOGRAPHICAL REFERENCES
=======================================================================
D.- Ameliorating Alzheimer's-like Pathology by Minocycline via
Inhibiting Cdk5/p25 Signaling (2022).
=======================================================================
1.) Progression of Lyme disease to Bell's Palsy despite treatment with
doxycycline.
2.) Minocycline as A Substitute for Doxycycline in Targeted Scenarios: A
Systematic Review.
3.) Minocycline in lepromatous leprosy.
4.) Efficacy of minocycline in single dose and at 100 mg twice daily for
lepromatous leprosy.
5.) Field trial on efficacy of supervised monthly dose of 600 mg
rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of
leprosy; first results.
plus minocycline, with or without rifampin, against Mycobacterium leprae
in mice and in lepromatous patients.
single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial
Group.
minocycline, with or without ofloxacin, against Mycobacterium leprae in
patients.
9.) Chronic Lyme borreliosis at the root of multiple sclerosis--is a
cure with antibiotics attainable?
10.) In-vitro and in-vivo antibiotic susceptibilities of Lyme disease
Borrelia isolated in China.
11.) Erythema migrans: three weeks treatment for prevention of late Lyme
borreliosis.
12.) No detection of Borrelia burgdorferi-specific DNA in erythema
migrans lesions after minocycline treatment.
13.) Susceptibility of the Lyme disease spirochete to seven
antimicrobial agents.
14.) Antibiotic therapy in early erythema migrans disease and related
disorders.
==================================================================
